within Pharmacolibrary.Drugs.N_NervousSystem.N07A_Parasympathomimetics.N07AA51_NeostigmineCombinations;

model NeostigmineCombinations
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.1e-06,
    adminDuration = 600,
    adminMass = 2.5 / 1000000,
    adminCount = 1,
    Vd = 0.00022,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00013000000000000002,
    k12 = 2.166666666666667e-06,
    k21 = 2.166666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>NeostigmineCombinations</td></tr><tr><td>ATC code:</td><td>N07AA51</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2.5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.22</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.8</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Neostigmine is a reversible acetylcholinesterase inhibitor used to enhance neuromuscular transmission. It is commonly used in the treatment of myasthenia gravis, reversal of non-depolarizing neuromuscular blockade post-surgery, and sometimes in the management of postoperative ileus and urinary retention. In combination products (ATC: N07AA51), it is typically combined with other cholinesterase inhibitors or anticholinergic agents. Neostigmine and its combinations are still approved for use today in many countries.</p><h4>Pharmacokinetics</h4><p>General adult population, both sexes, no specific disease or condition distinction, pharmacokinetic parameters derived primarily from pharmacokinetic studies in healthy volunteers with combination formulations.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N07AA51 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end NeostigmineCombinations;
